Quantum Genomics Société Anonyme announced the start of its pivotal REFRESH study in Asia. The REFRESH study should enable firibastat to be placed on the market at the end of 2023. The REFRESH study, a pivotal phase III study in difficult-to-treat and resistant hypertension, aims to demonstrate the efficacy of firibastat at 3 months and its long-term safety after a single daily dose of 1,000mg. The study will recruit 750 patients with resistant or difficult to treat hypertension at 106 centres in 14 countries in Europe, the United States, Canada, South Korea and Taiwan. The first patient was recruited last July. The interim results of this pivotal study, which will enable the marketing application to be submitted, will be available in mid-2023. The timelines for both the FRESH and REFRESH studies are perfectly aligned with the aim of putting firibastat on the market at the end of 2023.